Johnson & Johnson to acquire Proteologix for $850 million
J&J looks to gain access to the privately held company’s experimental atopic dermatitis treatments.
If you are not happy with the results below please do another search
J&J looks to gain access to the privately held company’s experimental atopic dermatitis treatments.
The companies announced they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study.
EVERSANA INTOUCH has announced a new leader for the medical communications function of the agency. Industry veteran Mary Manna Anderson has joined as the senior VP, managing director, head of medcomm and will oversee both global and U.S. medical communications services as well as future service expansion.
The settlement involves more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.
Novo Holdings announced today that it is buying a majority stake in the Austrian life sciences tools company Single Use Support, a provider of fluid management services.
When the Inflation Reduction Act rolled out in January 2023, a key tenet of the legislation was the associated Affordable Insulin Now Act, which caps the price of insulin products at $35 per month for Medicare Part D enrollees. Two months later, Novo Nordisk announced that in response, the firm was going to chop the cost of various insulin products by up to 75%.
Following an initial rejection in 2023, Ascendis Pharma on Tuesday said it faces another regulatory bump in the road for TransCon PTH with a three-month delay in the ongoing FDA review.
After missing their initial target in March 2024, Eisai and Biogen have initiated a rolling BLA for a subcutaneous maintenance formulation of Leqembi, which could offer a more convenient dosing schedule for Alzheimer’s disease patients.
Neuralink’s disclosure last week that tiny wires inside the brain of its first patient had pulled out of position is an issue the Elon Musk company has known about for years, according to five people familiar with the matter.
Collecting patient data through electronic PROs (ePROs) or electronic clinical outcome assessments (eCOAs) has been integral for patient centricity. These tools allow sponsors to meet patients where they are to gather real-time insights directly from the source, boosting patient retention and engagement. ePROs and eCOAs improve clinical trial outcomes with additional data points around a patient’s experience. However, the addition of consumer technologies that can collect ambient data points is poised to enhance outcomes even more, bringing treatments faster to those who need them most.